Literature DB >> 20603264

An online solid-phase extraction-liquid chromatography-tandem mass spectrometry method to study the presence of thyronamines in plasma and tissue and their putative conversion from 13C6-thyroxine.

M T Ackermans1, L P Klieverik, P Ringeling, E Endert, A Kalsbeek, E Fliers.   

Abstract

Thyronamines are exciting new players at the crossroads of thyroidology and metabolism. Here, we report the development of a method to measure 3-iodothyronamine (T(1)AM) and thyronamine (T(0)AM) in plasma and tissue samples. The detection limit of the method was 0.25 nmol/l in plasma and 0.30 pmol/g in tissue both for T(1)AM and for T(0)AM. Using this method, we were able to demonstrate T(1)AM and T(0)AM in plasma and liver from rats treated with synthetic thyronamines. Although we demonstrated the in vivo conversion of (13)C(6)-thyroxine ((13)C(6)-T(4)) to (13)C(6)-3,5,3'-triiodothyronine, we did not detect (13)C(6)-T(1)AM in plasma or brain samples of rats treated with (13)C(6)-T(4). Surprisingly, our method did not detect any endogenous T(1)AM or T(0)AM in plasma from vehicle-treated rats, nor in human plasma or thyroid tissue. Although we are cautious to draw general conclusions from these negative findings and in spite of the fact that insufficient sensitivity of the method related to extractability and stability of T(0)AM cannot be completely excluded at this point, our findings raise questions on the biosynthetic pathways and concentrations of endogenous T(1)AM and T(0)AM.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20603264     DOI: 10.1677/JOE-10-0060

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  7 in total

Review 1.  Novel thyroid hormones.

Authors:  Riccardo Zucchi; Grazia Rutigliano; Federica Saponaro
Journal:  Endocrine       Date:  2019-07-20       Impact factor: 3.633

2.  Biosynthesis of 3-iodothyronamine (T1AM) is dependent on the sodium-iodide symporter and thyroperoxidase but does not involve extrathyroidal metabolism of T4.

Authors:  Sarah A Hackenmueller; Maja Marchini; Alessandro Saba; Riccardo Zucchi; Thomas S Scanlan
Journal:  Endocrinology       Date:  2012-09-04       Impact factor: 4.736

Review 3.  Update on 3-iodothyronamine and its neurological and metabolic actions.

Authors:  Riccardo Zucchi; Alice Accorroni; Grazia Chiellini
Journal:  Front Physiol       Date:  2014-10-16       Impact factor: 4.566

Review 4.  Torpor: The Rise and Fall of 3-Monoiodothyronamine from Brain to Gut-From Gut to Brain?

Authors:  Hartmut H Glossmann; Oliver M D Lutz
Journal:  Front Endocrinol (Lausanne)       Date:  2017-05-31       Impact factor: 5.555

Review 5.  Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists.

Authors:  Rohit A Sinha; Eveline Bruinstroop; Brijesh K Singh; Paul M Yen
Journal:  Thyroid       Date:  2019-09       Impact factor: 6.568

6.  NMR-based metabolomics and breath studies show lipid and protein catabolism during low dose chronic T(1)AM treatment.

Authors:  J A Haviland; H Reiland; D E Butz; M Tonelli; W P Porter; R Zucchi; T S Scanlan; G Chiellini; F M Assadi-Porter
Journal:  Obesity (Silver Spring)       Date:  2013-05-29       Impact factor: 5.002

Review 7.  3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?

Authors:  Grazia Rutigliano; Lavinia Bandini; Simona Sestito; Grazia Chiellini
Journal:  Int J Mol Sci       Date:  2020-03-15       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.